Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA

January 27, 2024 updated by: Ahmed Gamal Thabit Mohamed, Assiut University

Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With Myocardial Infarction With Nonobstructive Coronary Arteries

This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of cardiovascular outcomes in Patients Presented with myocardial infarction with nonobstructive coronary arteries.

Study Overview

Status

Not yet recruiting

Conditions

Major Cardiovascular Events

Intervention / Treatment

Diagnostic test: Triglyceride glucose index TyG

Detailed Description

Acute myocardial infarction (AMI) remains the leading causes of high morbidity and mortality worldwide . Recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized because of the widespread use of coronary angiography. MINOCA occurs in 5%-10% of all AMI and they are younger and more often women compared to patients with AMI and obstructive coronary artery disease (CAD). The underlying causes of MINOCA are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA . Of note, several studies have found that the prognosis of MINOCA is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (CV) events despite the optimal secondary prevention treatments . Thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in MINOCA population.

Insulin resistance (IR), a critical mechanism of the pathogenesis of diabetes, not only contributes to the development of cardiovascular diseases (CVD), but also significantly correlates with adverse CV outcomes. Additionally, IR often coexists with obesity, hypertension, and dyslipidemia , and all of these are well-known risk factors of CVD. Recently, the triglyceride-glucose (TyG) index derived from fasting triglyceride (TG) and fasting blood glucose (FBG) levels has been proposed as a new and valid surrogate indicator of IR . Till now, many studies have found that the TyG index is positively correlated with metabolic disorders, arterial stiffness , carotid atherogenesis , coronary artery calcification , and subclinical or symptomatic CAD. Moreover, growing evidence has showed that the TyG index is an independent predictor of poor CV outcomes in general population and in different cohorts with CAD, including patients with AMI or acute coronary syndrome (ACS) with or without diabetes

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ahmed Gamal Thabit Mohamed
Phone Number: 01065476011
Email: ahmedgamal54011@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Myocardial infarction patients who were underwent PPCI and the coronary angiography showing insignificant lesions (stenosis less than 50% )

Description

Inclusion Criteria:

All patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA)
clinical symptoms
ECG : ischemic changes with or without ST segment elevation
Echocardiograpy : segmental wall motion abnormalities (SWMA)
positive cardiac enzymes
Coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%)

Exclusion Criteria:

All non confirmed diagnosis of MINOCA
cardiac
- non-ischemic cardiomyopathies
non-cardiac
- pulmonary embolism
- stroke
- sepsis
- ARDS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of major adverse cardiovascular events (MACE) Time Frame: along one year follow up .	including all-cause death, reinfarction, stroke, re-intervention hospitalization for unstable angina or heart failure)	along one year follow up .

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

Principal Investigator: Ayman khairy Mohamed Hassan, Cardiology Department
Principal Investigator: Khaled Mohamed Abdullah Mohamed, Cardiology Department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 20, 2024

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

September 27, 2023

First Submitted That Met QC Criteria